.png)
.png?width=700&height=291&name=Cell%202026%20Logo%20(Light).png "Cell 2026 Logo (Light)")
Programme
Day
From Model To Medicine: Fixing The Translation Gap
Panel Discussion• Are we building better models—or just more complex ones?
• Replacing or reducing animal models
o Refining models for regulatory compliance
• Achieving regulatory compliance
From Model To Medicine: Fixing The Translation Gap
Panel Discussion• Are we building better models—or just more complex ones?
• Replacing or reducing animal models
• Achieving regulatory compliance
Reduction Of Animal Bi-Products In Cell Cultures
Industry Presentation• FBS is a staple in cell culture but is associated with significant challenges regarding sustainability, costs and experimental variability
• Two chemically defined serum alternatives were identified and evaluated to understand feasibility, workflow impact, and cell growth
• Following this we identified across 70+ cell lines (adherent and suspension) that growth at 5% vs 10% serum was comparable for all lines evaluated
• We then compared multiple batches of FBS to assess whether results would be consistent at 5% and 10% serum.
• As a result, we are now moving away from high serum concentrations
GemPharmatech Presentation
Solution Provider PresentationWhat’s Next For Cell And Stem Cell Therapies? Challenges, Opportunities, And Clinical Translation
Roundtable DiscussionIngenza Presentation
Solution Provider PresentationTowards A Complex In Vitro Model Of Fatty Liver Disease
Industry PresentationGetinge Presentation
Solution Provider PresentationOvercoming Sterility Testing Challenges In CGT Analytical Development
Roundtable DiscussionHuman Brain Organoids In Drug Discovery
Industry PresentationAlphalyse Presentation
Solution Provider PresentationQC Approaches Post Manufacturing – Rapid Sterility
Industry PresentationAdvances In 3D Cultures And Their Role In Translational Research
Industry PresentationSapio Sciences Presentation
Solution Provider PresentationEnabling Affordable Gene Therapies Through Continuous Viral Vector Manufacturing
Industry PresentationProgrammable Gene Silencing Technology For Next-Generation Advanced Therapy Development
Industry PresentationDigital Twin Modelling For Accelerating Technical Transfer For Upstream Processes & As Digital Shadows In Commercial Manufacturing
Industry Presentationo Digital twin modelling is a simulation of active cell culture operations based on process understanding, first principles and historical and real time data. During the presentation you will:
• Identify critical data inputs for building reliable digital twin models for cell culture processes
• Use the tool to forecast the impact of process parameter changes, optimize sparger selection, and define gassing control strategies during technical transfer and scale-up
• Minimize at-scale technical runs during transfer through case study examples from Sanofi
• Verify PPQ batch consistency against historical CTM batches in real-time
• Quickly identify root causes and implement corrections when abnormalities arise
• Transition toward real-time optimization and disturbance rejection to reduce batch-to-batch variability and achieve optimal productivity and quality
Patient Derived Cells As New Approach Methodologies For More Predictive Oncology Models
Industry PresentationStem Cell-Derived Organoid Research
Industry PresentationrAAV Production Process Intensification Using Perfusion Bioreactor Technology
Industry PresentationMinimised Process Development By Recombinase Based Targeted Insertion For Superfast Clone Development Allowing Prefabricated Manufacturing Process
Industry PresentationNovo Nordisk Pharmatech A/S Presentation
Solution Provider PresentationNova Biomedical Presentation
Solution Provider PresentationBeckman Coulter Presentation
Solution Provider PresentationEngineered Cell Lines To Enable Multi-Specific Antibody Development
Industry PresentationBioThrust Presentation
Solution Provider PresentationWater Presentation
Solution Provider PresentationPHCBi Presentation
Solution Provider PresentationCell Line Database Development
Industry PresentationBPES Presentation
Solution Provider PresentationHamilton Presentation
Solution Provider PresentationFrom Model To Medicine: Fixing The Translation Gap
Panel Discussion• Are we building better models—or just more complex ones?
• Replacing or reducing animal models
• Achieving regulatory compliance
Featured Session: Restoring Hearing With Cell & Gene Therapies: From Bench To Bedside
Panel Discussion• Understanding the biological landscape
• Patient stratification & indication selection
• Development hurdles • Safety considerations
• Defining and measuring efficacy
Manufacture Of AVB-406, A BBB-Crossing AAV Vector For MAPT Knockdown In Alzheimer's Disease
Industry PresentationManufacturability Of Synthetic Products
Panel DiscussionHow can manufacturing systems be rapidly adapted for highly synthetic products?
Progressing forward to stable cell lines and what tech is needed
Nov-Viral Modification Of CART Cells With CRISPR For Improved Efficacy
Industry PresentationWhere Does Big Pharma Stand In CGTs – And What Comes Next?
Panel Discussion• Big pharma CGT strategy – in-house vs partnerships vs M&A?
• Manufacturing & scale – key bottlenecks in cost, capacity, complexity
• Access & commercialisation – How to overcome pricing, reimbursement, logistics barriers?
• Future innovation – Which next-gen tech (e.g. in vivo editing, non-viral delivery) will lead CGT next wave?
From Discovery To Deliverability: Building The Next Generation Of Cell Therapies
Panel Discussion• Choosing the right cell platform for the disease
• Overcoming barriers in solid tumours and complex indications
• From models to medicines
Building Investor Confidence And Translating Science Into Value
Panel Discussion• What do investors really look for in advanced therapy startups?
• What do biotech companies need from investors?
• Building an investor-ready biotech company
• Growth areas for investments landscape
• Where capital is flowing next
Donor Perspectives Of Advanced Therapies Development
Industry PresentationAdvanced Technologies Driving The Next Wave Of Gene Therapy
Industry PresentationFrom Discovery To Deliverability: Building The Next Generation Of Cell & Gene Therapies
Panel Discussion• Choosing the right cell platform for the disease
• Overcoming barriers in solid tumours and complex indications
• From models to medicines
Mapping Immune Vulnerabilities: CRISPR Screens for Target Discovery
Industry PresentationPhase Appropriate Analytical Strategies Including Comparability
Industry PresentationCracking In Vivo Delivery For Next-Generation Gene Therapies
Panel DiscussionFrom ex vivo to in vivo
Integration of CRISPR & other systems
Targeted delivery & available platforms
Targeting the right cell
Exploring The Future Of Autologous Stem Cell Therapy
Industry PresentationEmerging Regulatory Guidelines For Individualised Gene Therapies
Industry PresentationDeveloping Cutting-Edge Flow-Based Assays For Critical CMC Applications
Industry PresentationGene Therapy For Hearing Loss
Industry PresentationChanging Regulatory Environment For CGTs In 2027 (SoHO Regulations)
Industry PresentationManufacturing & Quality Control Of Early Phase ATMPs
Industry PresentationLentiviral Vector As Drug Product – A Gene Therapy Vector Facility Case Study
Industry PresentationAbselion Presentation
Solution Provider PresentationNK Cell Therapy Development
Industry PresentationClinical Trial Designs For Advanced Therapies Outside Of Oncology
Industry PresentationLessons Learned From Cross-Team & Multi-Site Collaboration To Improve Assay Transfer & Scalability
Industry PresentationCAR-T Clinical Trials In Hospitals
Industry PresentationWhy Regenerative Medicine Stalls And How Europe Can Fix It
Industry PresentationRegenerative medicine promises curative therapies, yet Europe has struggled to translate scientific excellence into clinical and commercial success. Drawing on a data driven landscaping of European and global RM ecosystems, this talk identifies structural bottlenecks and strategic levers, critical mass, capital deployment, manufacturing, and prioritization, required to engineer a trigger moment and unlock Europe’s regenerative medicine potential.
EU's AI Perspective
Solution Provider PresentationRegulatory Landscape & New Initiatives In The UK
Industry PresentationTitle To Be Confirmed
Industry PresentationDeveloping An AAV Gene Therapy For Hearing Loss
Industry PresentationBiological Reference Materials For The Advanced Therapy Field
Industry PresentationThe AI Reality Check: What’s Ready Now, What Isn’t, And How Do We Validate It Safely?
Panel Discussion• How do regulators expect AI tools to be validated?
• Where are the biggest risks of “black box” AI?
• What are the most immediate, realistic use cases?
Bio Rad Laboratories Presentation
Solution Provider PresentationNovel Strategies To Enhance CAR T-Cell Function In Solid Tumours
Industry PresentationRegenerative Macrophage Therapy From Bench To Bedside
Industry PresentationLeveraging Platform-Based RNA Silencing To Accelerate Rare Disease Therapeutic Development
Industry PresentationRewiring Tumour Cell Membranes To Unlock Chemotherapy Transporter Activation
Industry PresentationNew Gene Therapies For Obesity & Blindness
Industry PresentationDeveloping A World-First Regenerative Cell Therapy For Hearingloss
Industry PresentationInvestor-Focused Panel Discussion: Building Investor Confidence And Translating Science Into Value
Panel DiscussionWhat do investors really look for in advanced therapy startups?
What do biotech companies need from investors?
Building an investor-ready biotech company
Growth areas for investments landscape
Where capital is flowing next
Patient Access In Hospitals To Administer Cell & Gene Therapies
Industry PresentationSecretome Stem Cells In CNS Regeneration
Industry PresentationStrategic Analytical & Quality Control Components For Cell & Gene Therapy
Industry PresentationThe Academic Model Of Advanced Therapies From A Clinician’s Point Of View
Industry PresentationImproving Access To Cell Therapies For More Patient Globally Through The Development Of Novel Off-The-Shelf CIR (™) Technology
Industry PresentationQuality Control Strategies In Advanced CGTs
Panel Discussion• Which analytical attributes actually predict clinical and manufacturing risk?
• Moving from exploratory assays to release-relevant analytics
• Attributes for quality control
o Standardisation
o Prioritisation
Sartorius Presentation
Solution Provider PresentationChoice Of Potency Assays For Vascular Cell Therapies
Industry PresentationAseptic Presentation
Solution Provider PresentationDeveloping A QC Strategy
Industry PresentationSGS Presentation
Solution Provider PresentationBioMerieux UK Presentation
Solution Provider PresentationPre-Clinical/In Vivo Models For Advanced Therapies
Industry PresentationFUJIFILM Presentation
Solution Provider PresentationThe French Model Of ATMP Clinical Trials In Rare Diseases
Industry PresentationAccelerating Viral Gene Therapy Delivery With AI
Industry PresentationFrom Approval To Access: Why Cell & Gene Therapies Still Don’t Reach Patients
Panel Discussion• The clinician’s reality after approval
• Who carries the risk when outcomes are uncertain?
• Bridging the gap between developers and healthcare systems
• Who provides the education to ensure clinicians want to treat
patients with these options?
Building Investor Confidence And Translating Science Into Value
Panel Discussion• What do investors look for in advanced therapies such as cell and gene therapy and regenerative medicine, and across key areas like oncology, rare disease, and autoimmune disease?
• What does it take for biotech companies to become truly investor-ready in this space?
• Where is capital flowing next in advanced therapies, and what is driving those investment decisions?
Underpinning Advanced Therapy Development Using Microfluidic Approaches
Industry PresentationBeyond Silos: How Cell & Gene Therapies Fit Into The Broader Biotech & Treatment Landscape
Panel DiscussionHow do clinicians make modality choices in the real world?
How do CGTs complement — not replace — biologics and small molecules?
What lessons from traditional biotech should CGT learn?
Miltenyi Biotec Presentation
Solution Provider PresentationSolving the Capacity Crunch: How Do We Scale Advanced Therapy Operations Without Compromising Quality?
Roundtable DiscussionWhole System Engineering For Biopharmaceutical Development
Industry PresentationConsiderations For The Use Of AI To Support Regulator Decision-Making For Drug And Biological Products
Industry PresentationFrom Approval To Access: Why Cell & Gene Therapies Still Don’t Reach Patients
Panel Discussion• The Clinician’s reality after approval
• Who carries the risk when outcomes are uncertain?
• Bridging the gap between developers and healthcare systems
• Who provides the education to ensure clinicians want to treat patients with these options?
Overcoming Antigen Heterogeneity In Solid Cancer Using CARKey Technology
Industry PresentationProgen Presentation
Solution Provider PresentationMSC Therapies: From Decades Of Challenges To Commercial Approval
Industry PresentationWhere Advanced Therapies Will Be In 2030: Scientific, Clinical, Regulatory & Economic Futures
Panel Discussion• From breakthrough to platforms
• Clinical reality vs scientific promise
• Patient access & health system readiness
An Integrated Analytical Control Strategy – Execution Roadmap To Support Automation For Cell Therapies
Industry PresentationCMC Strategy For First-In-Class Allogeneic Innate Cell Therapies, Especially Neutrophil-Based Products
Industry PresentationDelivering Cell Therapies Into The NHS
Industry PresentationNavigating The Regulatory Lifecycle Of Advanced Therapies: Platforms, Manufacturing & Post-Market Approval Challenges
Panel Discussion• Practical challenges in pre- and post-approval compliance
• Preparing for future regulatory evolution
Scaling Autologous CAR-T Commercial Manufacturing
Industry PresentationRobust Manufacturing For Replacement Cell Therapies
Industry PresentationClosing The Gap: Connecting Upstream And Downstream Bioprocessing In Cell-Based Therapies
Panel DiscussionUpstream decisions that break downstream processes
Data continuity across the process
Designing for end-to-end process robustness
Designing Large Scale Cell Therapies For Real-World Access
Industry PresentationBuilding For The Future: Phase-Appropriate CMC Strategies
Industry PresentationDesigning An End-To-End Supply Chain For CGTs
Industry PresentationEU's AI Perspective
Solution Provider PresentationThe AI Reality Check: What’s Ready Now, What Isn’t, And How Do We Validate It Safely?
Panel Discussion• How do regulators expect AI tools to be validated?
• Where are the biggest risks of “black box” AI?
• What are the most immediate, realistic use cases?
Navigating The Regulatory Lifecycle Of Advanced Therapies: From Platform Approval To Manufacturing & Post-Market Evidence
Panel Discussion• Practical challenges in post-approval compliance
• Preparing for future regulatory evolution
External Sourcing & Supplier Selection
Industry PresentationEnsuring Cell Quality Throughout Manufacturing
Industry PresentationEppendorf Presentation
Solution Provider PresentationConsiderations For The Use Of AI To Support Regulator Decision-Making For Drug And Biological Products
Industry PresentationThermo Fisher Scientific Presentation
Solution Provider Presentation
Morning Break & Refreshments
Close of Day One & Networking Drinks Reception
Lunch Break
Lunch Break
End of Event
Afternoon Break & Refreshments
Morning Break & Refreshments
Afternoon Break & Refreshments
No sessions found matching your filters.
.jpg?length=600&name=1048e2c3-e8c7-4b49-9c34-abc9914eac2c-2-11764368speaker_photo-Jutta-Eichler-(2).jpg)
.png?length=600&name=1.GenScriptCorporation_Logo_EN_Horizontal_FullColor%20(2).png){kind=logo}
.png?length=600&name=9eaa81ee-5bbe-4b99-86f7-23f16ccb27a8-2-5668375logo-PersonalisCorporateLogo-(2).png)
.jpg?length=600&name=74dfee8e-75c7-46e0-9f51-31b709af2ede-2-5668375logo-Nanion_logo_black_RGB_300dpi-(2).jpg){kind=logo}
.jpg?width=2819&height=1174&name=74dfee8e-75c7-46e0-9f51-31b709af2ede-2-5668375logo-Nanion_logo_black_RGB_300dpi-(2).jpg){kind=logo}
